Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women

被引:31
作者
Mencej, Simona
Prezelj, Janez
Kocijancic, Andreja
Ostanek, Barbara
Marc, Janja
机构
[1] Univ Ljubljana, Fac Pharm, Chair Clin Biochem, SI-1000 Ljubljana, Slovenia
[2] Univ Ljubljana, Dept Endocrinol & Metab Dis, Med Ctr, SI-1000 Ljubljana, Slovenia
关键词
RANKL; TNFSF11; gene; osteoporosis; bone mineral density; single nucleotide polymorphism;
D O I
10.1016/j.maturitas.2006.03.004
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: The receptor activator of nuclear factor-kappa B ligand (RANKL) is recognized as one of the important regulators of osteoclastogenesis. The expression of the tumour necrosis factor superfamily, member 11 (TNFSF11) gene, which encodes for RANKL protein, is increased relative to the expression of osteoprotegrin in cases of senile osteoporosis with hip bone fracture. Our aim was to find polymorphisms in the TNFSF11] gene promoter and to investigate their possible association with bone mineral density (BMD). Methods: The TNFSF11 gene promoter region was screened for the presence of new sequence variations by direct sequencing. DNA sequencing revealed the presence of four sequence variations: -290C > T, -643C > T, -693G > C and - 1594G > A. Association of the discovered polymorphisms with BMD was investigated in 115 Slovenian postmenopausal women, using restriction fragment length polymorphism analysis. After a year, bone loss in the association with the identified sequence variations was evaluated in 43 postmenopausal women. Results: Three of the discovered sequence variations (-290C > T, -643C > T, -693G > Q proved to be polymorphic, whereas variation - 1594G > A was only found in one patient. The frequencies of genotypes were as follows: CC (27.8%), CT (43.5%), TT (28.7%) for -290C > T polymorphism; CC (23.5%), CT (47.8%), TT (28.7%) for -643C > T polymorphism; and GG (22.6%), GC (51.3%), CC (26. 1 %) for -693G > C polymorphism. A statistically significant association of genotype with BMD at the femoral neck was observed only in the -290C > T polymorphism. Genotype CC was associated with lower BMD than the TT genotype (P = 0.022). In polymorphism -693G > C, a significant difference in bone loss rate was observed in total hip (P = 0.011) and femoral neck BMD (P = 0.037). Conclusions: Four sequence variations were identified in the studied region of TNFSF11 gene promoter. Our results of preliminary clinical evaluation suggest that the -290C > T polymorphism in the TNFSF11 gene promoter could contribute to the genetic regulation of BMD. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:219 / 226
页数:8
相关论文
共 20 条
[1]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[2]   The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts [J].
Burgess, TL ;
Qian, YX ;
Kaufman, S ;
Ring, BD ;
Van, G ;
Capparelli, C ;
Kelley, M ;
Hsu, HL ;
Boyle, WJ ;
Dunstan, CR ;
Hu, S ;
Lacey, DL .
JOURNAL OF CELL BIOLOGY, 1999, 145 (03) :527-538
[3]   The ratio of messenger RNA levels of receptor activator of nuclear factor κB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis [J].
Fazzalari, NL ;
Kuliwaba, JS ;
Atkins, GJ ;
Forwood, MR ;
Findlay, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (06) :1015-1027
[4]   TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts [J].
Fuller, K ;
Wong, B ;
Fox, S ;
Choi, YW ;
Chambers, TJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (05) :997-1001
[5]   Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology [J].
Hofbauer, LC ;
Heufelder, AE .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (5-6) :243-253
[6]   Variation in genes involved in the RANK/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men [J].
Hsu, YH ;
Niu, TH ;
Terwedow, HA ;
Xu, X ;
Feng, Y ;
Li, ZP ;
Brain, JD ;
Rosen, CJ ;
Laird, N ;
Xu, XP .
HUMAN GENETICS, 2006, 118 (05) :568-577
[7]   Localization of RANKL (Receptor activator of NFκB ligand) mRNA and protein in skeletal and extraskeletal tissues [J].
Kartsogiannis, V ;
Zhou, H ;
Horwood, NJ ;
Thomas, RJ ;
Hards, DK ;
Quinn, JMW ;
Niforas, P ;
Ng, KW ;
Martin, TJ ;
Gillespie, MT .
BONE, 1999, 25 (05) :525-534
[8]   Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene [J].
Kitazawa, R ;
Kitazawa, S ;
Maeda, S .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1445 (01) :134-141
[9]   Vitamin D3 augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter [J].
Kitazawa, R ;
Kitazawa, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (02) :650-655
[10]   OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [J].
Kong, YY ;
Yoshida, H ;
Sarosi, I ;
Tan, HL ;
Timms, E ;
Capparelli, C ;
Morony, S ;
Oliveira-dos-Santos, AJ ;
Van, G ;
Itie, A ;
Khoo, W ;
Wakeham, A ;
Dunstan, CR ;
Lacey, DL ;
Mak, TW ;
Boyle, WJ ;
Penninger, JM .
NATURE, 1999, 397 (6717) :315-323